Breast Cancer Now media statements
We respond to NHS England breast cancer waiting times for November 2020
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to RxPONDER trial results that suggest postmenopausal women with early-stage breast cancer/low recurrence score could skip adjuvant chemo
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to the Scotland Cancer Recovery Plan
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
Response to the Spending Review 2020
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: September 2020 and Q2 20/21
NHS England cancer waiting times data from September 2020 show:
We respond to a BMJ Study that provides new estimates of breast cancer risks associated with HRT
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said:
We respond to news that the pandemic ‘threatens research as early career scientists look to leave’
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said,
We support recommendations for faster and wider access to innovative cancer treatments
Mia Rosenblatt, Associate Director of Policy and Influencing at Breast Cancer Now, said:
We respond to ‘plasmaMATCH’ trial that uses blood test to match women with breast cancer to a range of precision treatments
The plasmaMATCH trial investigates whether simple blood tests known as ‘liquid biopsies’ can benefit women with breast cancer, by tracking t...